Genetic testing in the European Union: Does economic evaluation matter?

European Journal of Health Economics

Volumn 13, Issue 5, 2012, Pages 651-661

  Antoñanzas, Fernando ^a   Rodriguez Ibeas R ^a   Hutter, M F ^a   Lorente, R ^a   Juarez C ^a   Pinillos, M ^a  

^a UNIVERSITY OF LA RIOJA   (Spain)

Author keywords

Decision making process; Economic evaluations; EU27; Genetic tests

Indexed keywords

DNA;

ALGORITHM; BREAST CANCER; CLINICAL ASSESSMENT TOOL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DNA DETERMINATION; DOWN SYNDROME; ECONOMIC EVALUATION; EUROPEAN UNION; GENETIC SCREENING; HEALTH CARE COST; HEMOCHROMATOSIS; HUMAN; HYPERCHOLESTEROLEMIA; MEDICAL DECISION MAKING; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TECHNOLOGY; THROMBOPHILIA;

CYSTIC FIBROSIS; DECISION MAKING; DOWN SYNDROME; EUROPEAN UNION; GENETIC DISEASES, INBORN; GENETIC TESTING; HEALTH CARE COSTS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MODELS, ECONOMIC; THROMBOPHILIA;

EID: 84865629662     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-011-0319-x     Document Type: Review

References (65)

1. J Balmaña J Sanz X Bonfill A Casado M Rué I Gich O Díez JM Sabaté M Baiget MC Alonso 2004 Genetic counseling program in familial breast cancer: analysis of its effectiveness, cost and cost-effectiveness ratio Int. J. Cancer 112 4 647 652 15382046 10.1002/ijc.20458
2. S Barré N Préaubert R Delaveyne M Cecchin 2005 An economic evaluation of screening for hereditary haemochromatosis in the French population Journal d'Economie Médicale 23 1 15 26
3. E Barrow R McMahon DG Evans E Levine J Hill 2008 Cost analysis of biomarker testing for mismatch repair deficiency in node-positive colorectal cancer Br. J. Surg. 95 7 868 875 18457354 10.1002/bjs.6172 1:STN:280: DC%2BD1czovFyjsQ%3D%3D
4. K Brain J Gray P Norman E France C Anglim G Barton E Parsons A Clarke H Sweetland M Tischkowitz J Myring K Stansfield D Webster K Gower-Thomas R Daoud C Gateley I Monypenny H Singhal L Branston J Sampson E Roberts R Newcombe D Cohen 2000 Randomized trial of a specialist genetic assessment service for familial breast cancer J. Natl Cancer Inst. 92 16 1345 1351 10944557 10.1093/jnci/92.16. 1345 1:STN:280:DC%2BD3cvjvVCktg%3D%3D
5. Caballero Villarraso J.; Villegas Portero R. "Denaturing high performance liquid chromatography (DHPLC). Use and utility in massive genotyping". Andalusian Agency for Health Technology Assessment (AETSA) 2006/2007
6. JJ Carlson NB Henrikson DL Veenstra SD Ramsey 2005 Economic analyses of human genetics services: a systematic review Genet. Med. 7 8 519 523 16247290 10.1097/01.GIM.0000182467.79495.e2
7. NW Calvert AB Morgan JW Catto FC Hamdy RL Akehurst P Mouncey S Paisley 2003 Effectiveness and cost-effectiveness of prognostic markers in prostate cancer Br. J. Cancer 88 1 31 35 12556955 10.1038/sj.bjc.6600630 1:STN:280:DC%2BD3s%2Fks12qsg%3D%3D
8. P Clark S Twaddle ID Walker L Scott IA Greer 2002 Cost-effectiveness of screening for the factor V Leiden mutation in pregnant women Lancet 359 9321 1919 1920 12057557 10.1016/S0140-6736(02)08740-8
9. D Cohen G Barton J Gray K Brain 2004 Health economics and genetic service development: a familial cancer genetic example Familial Cancer 3 1 61 67 15131408 10.1023/B:FAME.0000026812.87551.bf
10. K Cooper J Bryant J Picot A Clegg PR Roderick WM Rosenberg C Patch 2008 A decision analysis model for diagnostic strategies using DNA testing for hereditary haemochromatosis in at risk populations QJM 101 8 631 641 18522976 10.1093/qjmed/hcn070 1:STN:280:DC%2BD1cvnslejtw%3D%3D
11. HS Cuckle GA Richardson TA Sheldon P Quirke 1995 Cost effectiveness of antenatal screening for cystic fibrosis BMJ 311 7018 1460 1463 8520332 10.1136/bmj.311.7018.1460 1:STN:280:DyaK28%2Fps1eruw%3D%3D discussion 1463-1464
12. K Desboeuf L Molinier MO Carrere R Bugat M Boisseau M Machelard-Sauvage JJ Voigt J Pous 2001 Cost-effectiveness in diagnosis and treatment of carcinomas of unknown primary origin Bulletin du Cancer 88 11 1119 1127 11741806 1:STN:280:DC%2BD38%2FivFWqtA%3D%3D
13. Directorate E. (Biotechnology, Agriculture and Food), Survey on national legislation and activities in the filed of genetic testing in EU Member States. European Commission 2005
14. C Donaldson P Shackley M Abdalla 1997 Using willingness to pay to value close substitutes: carrier screening for cystic fibrosis revisited Health Econ. 6 2 145 159 9158967 10.1002/(SICI)1099-1050(199703)6:2<145::AID-HEC253>3. 0.CO;2-N 1:STN:280:DyaK2szgt1Ohsg%3D%3D
15. Drummond, M.F.; O'Brien, B.J.; Stoddart, G.L.; et al.: Methods for the Economics Evaluation of Health Care Programs, 2nd edn. Oxford University Press, New York (1997)
16. DM Eccles P Englefield MA Soulby IG Campbell 1998 BRCA1 mutations in Southern England Br. J. Cancer 77 12 2199 2203 9649133 10.1038/bjc.1998.366 1:CAS:528:DyaK1cXktlCmtLg%3D
17. F Fábregues D Tàssies JC Reverter F Carmona A Ordinas J Balasch 2004 Prevalence of thrombophilia in women with severe ovarian hyperstimulation syndrome and cost-effectiveness of screening Fertil. Steril. 81 4 989 995 15066453 10.1016/j.fertnstert.2003.09.042
18. RE Gilbert C Augood R Gupta AE Ades S Logan M Sculpher JH van der Meulen 2001 Screening for Down's syndrome: effects, safety, and cost effectiveness of first and second trimester strategies BMJ 323 7310 423 425 11520837 10.1136/bmj.323.7310.423 1:STN:280:DC%2BD3Mvns12msw%3D%3D
19. B Goard L Kate G Evers-Kiebooms S Aymé 2003 Population genetic screening programmes: principles, techniques, practices, and policies Eur. J. Genet. 11 Sppl 2 549 587
20. DE Goldgar DF Easton 1997 Optimal strategies for mapping complex diseases in the presence of multiple loci Am. J. Hum. Genet. 60 5 1222 1232 9150170 1:STN:280:DyaK2s3psVCitg%3D%3D
21. H Goldstein J Philip 1990 A cost-benefit analysis of prenatal diagnosis by amniocentesis in Denmark Clin. Genet. 37 4 241 263 2112433 10.1111/j.1399-0004.1990.tb04187.x 1:STN:280:DyaK3c3nsFOrtA%3D%3D
22. F Guadagni P Ferroni S Carlini S Mariotti A Spila S Aloe R D'Alessandro MD Carone A Cicchetti A Ricciotti I Venturo P Perri F Di Filippo F Cognetti C Botti M Roselli 2001 A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study Clinic. Cancer Res. 7 8 2357 2362 1:CAS:528:DC%2BD3MXmsVOmt7k%3D
23. O Gustafsson P Carlsson U Norming CR Nyman H Svensson 1995 Cost-effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men Prostate 26 6 299 309 7540297 10.1002/pros.2990260605 1:STN:280: DyaK2MzgtlOjug%3D%3D
24. JE Haddow LA Bradley GE Palomaki RA Doherty 1999 Issues in implementing prenatal screening for cystic fibrosis: results of a working conference J. Med. Screen. 6 2 60 66 10444721 1:STN:280:DyaK1MzntlOntQ%3D%3D
25. A Hagen HK Hessabi V Gorenoi MP Schönermark 2008 Cost-effectiveness evaluation of predictive molecular diagnostics using the example of hereditary non-polyposis colorectal cancer (HNPCC) Gesundheitswesen 70 1 18 27 18273760 10.1055/s-2007-1022526 1:STN:280:DC%2BD1c7hsVyruw%3D%3D
26. O Haillot A Villers M Soulie JC Baron 1998 Screening of cancer of the prostate (IV). Economic approach: the costs of screening tests and treatment. Members of the sub-committee of the prostate of CCAFU Prog. Urol. 8 4 517 523 9834514 1:STN:280:DyaK1M%2FltFGkuw%3D%3D
27. M Hoogendoorn SM Evers PC Schielen ML van Genugten GA de Wit AJ Ament 2008 Costs and effects of prenatal screening methods for down syndrome and neural tube defects Community Genet. 11 6 359 367 18690004
28. MF Hutter F Antoñanzas 2009 Health economics evaluations: a comparative analysis of European studies Pharmacoeconomics 27 7 561 570 19663527 10.2165/11310060-000000000-00000
29. P Javaher H Käärläinen U Kristoffersson I Nippert 2008 EuroGentest: DNA-Based testing for heritable disorders in Europe Community Genet. 11 75 120 18204250 10.1159/000111984
30. JF Jusot C Colin 2001 Cost-effectiveness analysis of strategies for hepatitis C screening in French blood recipients Eur. J. Public Health 11 4 373 379 11766476 10.1093/eurpub/11.4.373 1:STN:280:DC%2BD38%2FjvFGiuw%3D%3D
31. W Kievit JH de Bruin EM Adang JL Severens JH Kleibeuker RH Sijmons TJ Ruers FM Nagengast HF Vasen JH van Krieken MJ Ligtenberg N Hoogerbrugge 2005 Cost effectiveness of a new strategy to identify HNPCC patients Gut 54 1 97 102 15591512 10.1136/gut.2004.039123 1:STN:280:DC%2BD2cnhslWntg%3D%3D
32. L Kruper J Kurichi S Sonnad 2007 Methodologic quality of cost-effectiveness analyses of surgical procedures Ann. Surg. 245 147 151 17197978 10.1097/01.sla.0000231802.83152.59
33. PJ Marang-van de Mheen AH ten Asbroek L Bonneux GJ Bonsel NS Klazinga 2002 Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in The Netherlands Eur. Heart J. 23 24 1922 1930 12473254 10.1053/euhj.2002.3281 1:STN:280:DC%2BD38jhtFWlsg%3D%3D
34. M Marchetti S Quaglini G Barosi 2001 Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A QJM 94 7 365 372 11435632 10.1093/qjmed/94.7.365 1:STN:280: DC%2BD3MznvFCqsg%3D%3D
35. D Marks M Thorogood AW Neil D Wonderling SE Humphries 2003 Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening J. Public Health Med. 25 1 47 52 12669918 10.1093/pubmed/fdg010
36. D Marks D Wonderling M Thorogood H Lambert SE Humphries H Andrew W Neil 2002 Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia Bri. Med. J. 324 7349 1303 1306 10.1136/bmj.324.7349.1303
37. ZH Miedzybrodzka Z Yin KF Kelly NE Haites 1994 Evaluation of laboratory methods for cystic fibrosis carrier screening: reliability, sensitivity, specificity, and costs J. Med. Genet. 31 7 545 550 7525964 10.1136/jmg.31.7.545 1:STN:280:DyaK2M%2FlsFKjtg%3D%3D
38. Z Miedzybrodzka J Semper P Shackley M Abdalla C Donaldson 1995 Stepwise or couple antenatal carrier screening for cystic fibrosis?: women's preferences and willingness to pay J. Med. Genet. 32 4 282 283 7643357 10.1136/jmg.32.4.282 1:STN:280:DyaK2MzntFSrsg%3D%3D
39. PJ Neumann F Chi-Hui JT Cohen 2009 30 years of pharmaceutical cost-utility analyses. Growth, diversity and methodological improvement Pharmacoeconomics 27 10 861 872 19803540 10.2165/11312720-000000000-00000
40. M Nielsen FJ Hes HF Vasen WB van den Hout 2007 Cost-utility analysis of genetic screening in families of patients with germline MUTYH mutations BMC Med. Genet. 8 42 17605803 10.1186/1471-2350-8-42
41. R Nielsen D Gyrd-Hansen 2002 Prenatal screening for cystic fibrosis: an economic analysis Health Econ. 11 4 285 299 12007162 10.1002/hec.652
42. J Oliva J López-Bastida SG Moreno P Mata R Alonso 2009 Cost-effectiveness analysis of a genetic screening program in the close relatives of Spanish patients with familial hypercholesterolemia Rev. Esp. Cardiol. 62 1 57 65 19150015 10.1016/S0300-8932(09)70021-1
43. Palareti, G.; Legnani, C.; Frascaro, M.; Flamigni, C.; Gammi, L.; Gola, G.; Fuschini, G.; Coccheri, S.: Screening for activated protein C resistance before oral contraceptive treatment: a pilot study. Contraception. 59, 293-299 (1999)
44. C Patch P Roderick W Rosenberg 2005 Factors affecting the uptake of screening: a randomised controlled non-inferiority trial comparing a genotypic and a phenotypic strategy for screening for haemochromatosis J. Hepatol. 43 1 149 155 15876471 10.1016/j.jhep.2005.02.018 1:CAS:528:DC%2BD2MXlt1Ghs7c%3D
45. J Pinto-Basto B Guimaraes E Rantanen P Javaher I Nippert JJ Cassiman H Kääriäinen U Kristoffersson J Schmidtke J Sequeiros 2010 Scope of definitions of genetic testing: evidence from a EuroGentest survey J. Community Genet. 1 29 35 22422358 10.1007/s12687-010-0004-2
46. V Piñol A Castells M Andreu S Castellví-Bel C Alenda X Llor RM Xicola F Rodríguez-Moranta A Payá R Jover X Bessa Gastrointestinal Oncology Group of the Spanish Gastroenterological Association 2005 Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer JAMA 293 16 1986 1994 15855432 10.1001/jama.293.16.1986
47. W Rogowski 2006 Genetic screening by DNA technology: a systematic review of health economic evidence Int. J. Technol. Assess. Health Care. 22 3 327 337 16984061 10.1017/S0266462306051221
48. W Rogowski 2007 Current impact of gene technology on health care: a map of economic assessments Health Policy 80 340 357 16678930 10.1016/j.healthpol. 2006.03.009
49. WH Rogowski 2009 The cost-effectiveness of screening for hereditary hemochromatosis in Germany: a remodeling study Med. Decis. Making 29 2 224 238 19182214 10.1177/0272989X08327112
50. Ryan, M.; Diack, J.; Watson, V.; Smith, N.: Rapid prenatal diagnostic testing for Down syndrome only or longer wait for full karyotype: the views of pregnant women. Prenat. Diagn. 13(13), 1206-1211 (2005)
51. O Schöffski J Schmidtke M Stuhrmann 2000 Cost-effectiveness of population-based genetic hemochromatosis screening Community Genet. 3 2 11 10.1159/000016220
52. V Seror F Muller JP Moatti C Le Gales A Boue 1993 Economic assessment of maternal serum screening for Down's syndrome using human chorionic gonadotropin Prenat. Diag. 13 4 281 292 10.1002/pd.1970130407 1:STN:280:DyaK3s3otFGhtA%3D%3D
53. M Serra-Prat P Gallo AJ Jovell M Aymerich MD Estrada 1998 Trade-offs in prenatal detection of Down syndrome Am. J. Public Health 88 551 557 9550991 10.2105/AJPH.88.4.551 1:STN:280:DyaK1c3ht1enug%3D%3D
54. Sevilla, C.; Moatti, J.P.; Julian-Reynier, C.; Eisinger, F.; Stoppa-Lyonnet, D.; Bressac-de Paillerets, B.; Sobol, H.: Testing for BRCA1 mutations: a cost-effectiveness analysis. Eur. J. Hum. Genet. 10(10), 599-606 (2002)
55. TA Sheldon J Simpson 1991 Appraisal of a new scheme for prenatal screening for Down's syndrome BMJ 302 6785 1133 1136 1710520 10.1136/bmj.302.6785.1133 1:STN:280:DyaK3M3lsFOgsg%3D%3D
56. N Simpson R Anderson F Sassi A Pitman P Lewis K Tu H Lannin 2005 The cost-effectiveness of neonatal screening for cystic fibrosis: an analysis of alternative scenarios using a decision model Cost Eff. Resour. Alloc. 3 8 16091139 10.1186/1478-7547-3-8
57. EJ Sims M Mugford A Clark D Aitken J McCormick G Mehta A Mehta 2007 UD Cystic Fibrosis Database Steering Committee. "Economic implications of newborn screening for cystic fibrosis: a cost of illness retrospective cohort study" Lancet 369 1187 1195 17416263 10.1016/S0140-6736(07)60565-0
58. M Stuhrmann C Strassburg J Schmidtke 2005 Genotype-based screening for hereditary haemochromatosis. I: technical performance, costs and clinical relevance of a German pilot study Eur. J. Hum. Genet. 13 1 69 78 15483651 10.1038/sj.ejhg.5201287 1:CAS:528:DC%2BD2cXhtVOnurjK
59. AA Van der Riet BA van Hout FF Rutten 1997 Cost effectiveness of DNA diagnosis for four monogenic diseases J. Med. Genet. 34 9 741 745 9321760 10.1136/jmg.34.9.741
60. S Vegter C Boersma M Rozenbaum B Wilffert G Navis MJ Posta 2008 Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines Pharmacoeconomics 26 7 569 587 18563949 10.2165/00019053-200826070-00005 1:CAS:528:DC%2BD1cXpslWqtbY%3D
61. FA Weijers-Poppealaars MF Wildhagen L Henneman MC Cornel LP Kate 2005 Preconception cystic fibrosis carrier screening: costs and consequences Genet. Test 9 2 158 166 10.1089/gte.2005.9.158
62. MF Wildhagen LP ten Kate JD Habbema 1998 Screening for cystic fibrosis and its evaluation Br. Med. Bull. 54 4 857 875 10367419 10.1093/oxfordjournals. bmb.a011734 1:STN:280:DyaK1M3psFCqtw%3D%3D
63. MF Wildhagen BM Hilderink JG Verzijl JB Verheij L Kooij T Tijmstra LP Ten Kate JD Habbema 1998 Costs, effects, and savings of screening for cystic fibrosis gene carriers J. Epidemiol. Community Health 52 7 459 467 9799881 10.1136/jech.52.7.459 1:STN:280:DyaK1M%2Fhs1alsQ%3D%3D
64. D Wonderling MA Umans-Eckenhausen D Marks JC Defesche JJ Kastelein M Thorogood 2004 Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands Semin. Vasc. Med. 4 1 97 104 15199439 10.1055/s-2004-822992
65. Zika E.; Gurwitz D.; Ibarreta D. Pharmacogenetics and Pharmacogenomics: State-of-the-art and potential socio-economic impacts in the EU. Report EUR 22214 EN. Brusseles, European Commission, Joint Research Centre, Institute for Prospective Technological Studies. 2006. ( www.jrc.es/home/pages/detail.cjm?prs= 1387 )